A Sydney company has become the first in Australia to earn a manufacturing licence for viral vectors, a milestone it says strengthens the nation's capacity to make advanced gene and cell therapies at home rather than relying on overseas suppliers.
Viral Vector Manufacturing Facility, known as VVMF, announced that the Therapeutic Goods Administration has granted it a Licence to Manufacture Therapeutic Goods, commonly called a GMP licence, for its facility in Westmead.
The company describes itself as Australia's first and only Contract Development and Manufacturing Organisation dedicated to viral vectors, the biological delivery vehicles that carry genetic material into cells and underpin many emerging treatments for cancers and rare diseases.
The licence permits VVMF to manufacture replication-incompetent viral vectors made with recombinant technology under good manufacturing practice conditions. It covers production of both sterile active pharmaceutical ingredients and sterile medicinal products, along with the quality control testing that must accompany them. Approval followed what the company called a comprehensive assessment of its facilities, quality systems, manufacturing operations and operational capability.
The facility sits within Sydney's Westmead Health and Innovation Precinct and offers what VVMF describes as end-to-end support for developers, spanning process development, analytical development, GMP manufacturing and quality control testing. That range is intended to let clients move programs from early development through clinical translation without sending work offshore.
Stephen Thompson, VVMF's chief executive, called the licence a defining moment for the company and for the sector more broadly. "This achievement establishes a sovereign capability that will enable innovators to access world-class viral vector manufacturing services locally while supporting the growth of Australia's cell and gene therapy ecosystem, ultimately helping bring these therapies closer to the patients who need them," he said.
Maria Adesida, the company's chief quality officer, framed the approval as validation of work built from the ground up. "The granting of our TGA Manufacturing Licence demonstrates the strength of our quality systems, facility, operational controls and manufacturing capability," she said, adding that VVMF can now deliver GMP-compliant viral vector manufacturing services that support the next generation of cell and gene therapies.
